{"id":"NCT02040428","sponsor":"Ethicon, Inc.","briefTitle":"The Fibrin Pad CV Phase III Study","officialTitle":"A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-01","primaryCompletion":"2015-07-01","completion":"2015-09-01","firstPosted":"2014-01-20","resultsPosted":"2017-08-15","lastUpdate":"2017-08-15"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Cardiovascular Disease"],"interventions":[{"type":"BIOLOGICAL","name":"EVARREST™ Fibrin Sealant Patch","otherNames":[]},{"type":"BIOLOGICAL","name":"Topical hemostat","otherNames":[]}],"arms":[{"label":"EVARREST™ Fibrin Sealant Patch","type":"EXPERIMENTAL"},{"label":"Topical hemostat","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.","primaryOutcome":{"measure":"Number of Participants With Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application.","timeFrame":"Intraoperative, 3 minutes following treatment application","effectByArm":[{"arm":"EVARREST Fibrin Sealant Patch","deltaMin":57,"sd":null},{"arm":"TachoSil","deltaMin":36,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":24,"countries":["United States","Australia","Belgium","Japan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":75},"commonTop":["Atrial fibrillation","Pleural effusion","Anaemia","Nausea","Hypotension"]}}